Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[In women receiving gonadotropin-releasing hormone agonist (n = 1) or oral contraceptives (n = 1), after the menopause (n = 2), and with irregular vaginal bleeding (n = 1), oxytocin receptor levels in leiomyoma and myometrium were unchanged but were reduced in anovulatory cycles (amenorrhea, n = 2).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP397432.RAoyX2SpKf95GcaTnAAmlcMZD9Qy_hxPzZRH2BaYOotf4130_assertion description "[In women receiving gonadotropin-releasing hormone agonist (n = 1) or oral contraceptives (n = 1), after the menopause (n = 2), and with irregular vaginal bleeding (n = 1), oxytocin receptor levels in leiomyoma and myometrium were unchanged but were reduced in anovulatory cycles (amenorrhea, n = 2).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP397432.RAoyX2SpKf95GcaTnAAmlcMZD9Qy_hxPzZRH2BaYOotf4130_provenance.
• NP421984.RAKvKaXDAyDi5twf89QZ71rsMV_J02DYUk_JJ_lFXa2es130_assertion description "[In women receiving gonadotropin-releasing hormone agonist (n = 1) or oral contraceptives (n = 1), after the menopause (n = 2), and with irregular vaginal bleeding (n = 1), oxytocin receptor levels in leiomyoma and myometrium were unchanged but were reduced in anovulatory cycles (amenorrhea, n = 2).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP421984.RAKvKaXDAyDi5twf89QZ71rsMV_J02DYUk_JJ_lFXa2es130_provenance.
• NP604692.RAc711wNJxpol5A1peBVfjsBAXZJHARDoI_-zzN8_7qhk130_assertion description "[In women receiving gonadotropin-releasing hormone agonist (n = 1) or oral contraceptives (n = 1), after the menopause (n = 2), and with irregular vaginal bleeding (n = 1), oxytocin receptor levels in leiomyoma and myometrium were unchanged but were reduced in anovulatory cycles (amenorrhea, n = 2).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP604692.RAc711wNJxpol5A1peBVfjsBAXZJHARDoI_-zzN8_7qhk130_provenance.
• NP604693.RAQI6tK8jWQ1U6iDWCvwYpOBP7wnARBNRbTom5ey0PC8M130_assertion description "[In women receiving gonadotropin-releasing hormone agonist (n = 1) or oral contraceptives (n = 1), after the menopause (n = 2), and with irregular vaginal bleeding (n = 1), oxytocin receptor levels in leiomyoma and myometrium were unchanged but were reduced in anovulatory cycles (amenorrhea, n = 2).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP604693.RAQI6tK8jWQ1U6iDWCvwYpOBP7wnARBNRbTom5ey0PC8M130_provenance.
• assertion description "[In women receiving gonadotropin-releasing hormone agonist (n = 1) or oral contraceptives (n = 1), after the menopause (n = 2), and with irregular vaginal bleeding (n = 1), oxytocin receptor levels in leiomyoma and myometrium were unchanged but were reduced in anovulatory cycles (amenorrhea, n = 2).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[In women receiving gonadotropin-releasing hormone agonist (n = 1) or oral contraceptives (n = 1), after the menopause (n = 2), and with irregular vaginal bleeding (n = 1), oxytocin receptor levels in leiomyoma and myometrium were unchanged but were reduced in anovulatory cycles (amenorrhea, n = 2).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[In women receiving gonadotropin-releasing hormone agonist (n = 1) or oral contraceptives (n = 1), after the menopause (n = 2), and with irregular vaginal bleeding (n = 1), oxytocin receptor levels in leiomyoma and myometrium were unchanged but were reduced in anovulatory cycles (amenorrhea, n = 2).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP1404941.RAcFYHjlBhSxTLNphf7WNVPMI4QMP16oEEAF-voiR4GcA130_assertion description "[In women receiving gonadotropin-releasing hormone agonist (n = 1) or oral contraceptives (n = 1), after the menopause (n = 2), and with irregular vaginal bleeding (n = 1), oxytocin receptor levels in leiomyoma and myometrium were unchanged but were reduced in anovulatory cycles (amenorrhea, n = 2).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1404941.RAcFYHjlBhSxTLNphf7WNVPMI4QMP16oEEAF-voiR4GcA130_provenance.
• NP604587.RAAMem_7WhbbfgrxmUWHce0mUcVuRDwiRa7LpIEHaV6A0130_assertion description "[In women receiving gonadotropin-releasing hormone agonist (n = 1) or oral contraceptives (n = 1), after the menopause (n = 2), and with irregular vaginal bleeding (n = 1), oxytocin receptor levels in leiomyoma and myometrium were unchanged but were reduced in anovulatory cycles (amenorrhea, n = 2).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP604587.RAAMem_7WhbbfgrxmUWHce0mUcVuRDwiRa7LpIEHaV6A0130_provenance.
• NP604658.RAlQJzgSuNdHqfMCHjb3rvNknGrSKcqmcPktB-u_xoBXw130_assertion description "[In women receiving gonadotropin-releasing hormone agonist (n = 1) or oral contraceptives (n = 1), after the menopause (n = 2), and with irregular vaginal bleeding (n = 1), oxytocin receptor levels in leiomyoma and myometrium were unchanged but were reduced in anovulatory cycles (amenorrhea, n = 2).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP604658.RAlQJzgSuNdHqfMCHjb3rvNknGrSKcqmcPktB-u_xoBXw130_provenance.
• NP1404944.RADmPGAZGm9hTT0ydt-wsJ3TRYNRI4GhNKhs7R_9QrzBo130_assertion description "[In women receiving gonadotropin-releasing hormone agonist (n = 1) or oral contraceptives (n = 1), after the menopause (n = 2), and with irregular vaginal bleeding (n = 1), oxytocin receptor levels in leiomyoma and myometrium were unchanged but were reduced in anovulatory cycles (amenorrhea, n = 2).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1404944.RADmPGAZGm9hTT0ydt-wsJ3TRYNRI4GhNKhs7R_9QrzBo130_provenance.
• NP1404945.RAD8X97PgYyplWHLw0nQULN2oaxz8Xhf55DJyN5Sl0j7U130_assertion description "[In women receiving gonadotropin-releasing hormone agonist (n = 1) or oral contraceptives (n = 1), after the menopause (n = 2), and with irregular vaginal bleeding (n = 1), oxytocin receptor levels in leiomyoma and myometrium were unchanged but were reduced in anovulatory cycles (amenorrhea, n = 2).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1404945.RAD8X97PgYyplWHLw0nQULN2oaxz8Xhf55DJyN5Sl0j7U130_provenance.
• NP1404946.RAp267bApiXoP85mzAesdqYj36d2UP8OmRgAPhv8Ag0E4130_assertion description "[In women receiving gonadotropin-releasing hormone agonist (n = 1) or oral contraceptives (n = 1), after the menopause (n = 2), and with irregular vaginal bleeding (n = 1), oxytocin receptor levels in leiomyoma and myometrium were unchanged but were reduced in anovulatory cycles (amenorrhea, n = 2).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1404946.RAp267bApiXoP85mzAesdqYj36d2UP8OmRgAPhv8Ag0E4130_provenance.